Mankind Pharma Ltd share price logo

Mankind Pharma Ltd (MANKIND)


Get free price alerts. Set up your Free investment account to get Live Prices.
Q3 '23 Results
News and Events


  • Day's Low

    Day's High

  • 52 Week's Low

    52 Week's High

1 Month Return+ 2.28 %
3 Month Return+ 2.6 %
1 Year Return+ 38.08 %
Previous Close₹2,240.20
Upper Circuit-
Lower Circuit-
Market Cap₹89,750.28Cr

Analyst Rating

based on 14 analysts


Based on 14 analysts offering long term price targets for Mankind Pharma Ltd. An average target of ₹2266.93

Source: S&P Global Market Intelligence

Company Information

Mankind Pharma Ltd. was established in 1991 as a Private Limited Company. In 2005 it was converted to a Public Limited Company and the name changed to Mankind Pharma Limited. The Company is engaged in the development, manufacturing and marketing of a range of pharmaceuticals and consumer healthcare products, and is active in acute and chronic therapeutic areas such as anti-infectives, cardiovascular and gastrointestinal treatments, antidiabetic and neuro/CNS medicines, vitamins, minerals and nutrients. In 2004, they entered the chronic pharmaceutical segment, and have added further products over the years, including ophthalmic products, consumer healthcare products, animal healthcare products and specialty therapeutic divisions. They operate 23 manufacturing facilities across India and had 2181 manufacturing personnel as of March 31, 2021. It is now planning to raise capital through the public offering of 40058844 equity shares, with a total installed capacity of 40.77 billion units across a range of products.

Share Price: ₹2240.60 per share as on 14 Jun, 2024 04:01 PM
Market Capitalisation: ₹89,750.28Cr as of today
Revenue: ₹2,441.10Cr as on March 2024 (Q1 24)
Net Profit: ₹476.59Cr as on March 2024 (Q1 24)
Listing date: 09 May, 2023
OrganisationMankind Pharma Ltd
HeadquartersNew Delhi
E-voting on sharesClick here to vote

Key events for Mankind Pharma Ltd

  • Mankind Pharma Launches Campaign, Receives Buy Rating from MOFSL - 14 Jun, 2024

    Mankind Pharma receives a buy rating from broker MOFSL due to its leadership in the prescription market and strong presence in untapped markets. The company also launches a campaign to address blood donor shortages in India.

  • Motilal Oswal Recommends Buy Rating for Mankind Pharma - 13 Jun, 2024

    Motilal Oswal has initiated coverage on Mankind Pharma with a buy rating and a target price of Rs 2,650. The company is working on multiple levers to boost growth over the next three to five years. Domestic brokerage firm expects a 16% earnings CAGR for Mankind over FY24-27.

  • Mankind Pharma Plans to Bid for Bharat Serums and Vaccines - 12 Jun, 2024

    Mankind Pharma is reportedly in talks with global private equity firms to make a joint bid for Bharat Serums and Vaccines, which has been put on the block by Advent International. The company plans to raise up to ₹7,500 crore through a qualified institutional placement and has increased its borrowing limit to ₹12,500 crore.

  • Warburg Pincus, ChrysCapital and others in race to acquire BSV Group - 10 Jun, 2024

    Mankind Pharma is among the consortium of bidders for BSV Group, valued at ₹12,000-13,000 crore ($1.4-1.5 billion). Dr Reddys Laboratories may also join the race. Final offers expected in July.

  • Pharmaceutical Companies Face Scrutiny Over Tax Evasion - 04 Jun, 2024

    The Directorate General of GST Intelligence (DGGI) is intensifying scrutiny of suspected tax evasion by pharmaceutical companies, including Mankind Pharma. Notices have been sent to all major drug manufacturers, such as Sun Pharma, Zydus Healthcare, and Cipla.

  • Mankind Pharma's Strong Financials Could Lead to Long-Term Growth - 29 May, 2024

    Despite a recent 11% drop in share price, Mankind Pharma's strong financial health and return on equity (ROE) suggest potential for long-term growth. The company's net income growth and reinvestment of profits into the business are also positive indicators. Industry analyst forecasts predict continued growth.

  • Mankind Pharma's Market Share Climbs to 37.4% - 27 May, 2024

    Mankind Pharma is experiencing a positive trend, with their market share reaching an impressive 37.4% and the cardiac and anti-diabetic segment hitting an all-time high in Q4FY2024. The company plans for new drug launches and expansion into higher-margin consumer healthcare markets, signaling a bright future. Analysts predict a price target of Rs 2,410 in 8-10 months.

  • Mankind Pharma Plans Expansion and Acquisitions - 24 May, 2024

    Mankind Pharma is set to invest ₹200 crore in two new manufacturing plants as part of its expansion plans. The company has also approved raising ₹7,500 crore and increasing its borrowing limit to ₹12,500 crore for potential acquisitions. Mankind Pharma has outlined four key factors that will guide all acquisition decisions.

  • Mankind Pharma Reports Strong Financial Results for March 2024 - 20 May, 2024

    Mankind Pharma's net sales for March 2024 increased by 18.92% YoY, with a quarterly net profit of Rs. 471.24 crore, up 65.09% from the previous year. The company's EPS also rose to Rs. 11.76 in March 2024. Mankind Pharma shares closed at 2,090.65 on May 17, 2024 (NSE) and have given returns of 3.86% over the last 6 months and 54.20% over the last 12 months.

  • Mankind Pharma Reports Strong Q4 Results - 16 May, 2024

    Mankind Pharma reports strong Q4 results with an 18.9% rise in revenue at Rs 2,441 crore and a net profit of Rs 477 crore, up 62.3% from last year. The company is looking for assets for acquisition and has approved fundraise of up to Rs 7,500 crore. Mankind Pharma's stock volume surged on NSE, but its shares fell around 5% due to clarification on acquisition rumors.

Insights on Mankind Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    FII Holding Up


    Foreign Institutions have increased holdings from 6.74% to 9.87% in Mar 2024 quarter


    Profit Spike


    Netprofit is up for the last 2 quarters, 453.76 Cr → 471.24 Cr (in ₹), with an average increase of 3.7% per quarter


    Price Rise


    In the last 3 months, MANKIND stock has moved up by 2.6%


    MF Holding Up


    Mutual Funds have increased holdings from 7.55% to 8.57% in Mar 2024 quarter


    Promoter Holding Down


    Promoters have decreased holdings from 76.50% to 74.88% in Mar 2024 quarter


    Retail Holding Down


    Retail Investor have decreased holdings from 6.97% to 4.11% in Mar 2024 quarter


    Revenue Fall


    Revenue is down for the last 3 quarters, 2.77K Cr → 2.53K Cr (in ₹), with an average decrease of 4.3% per quarter

Mankind Pharma Ltd Valuation

Mankind Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (41.33x)

May 24, 2023

Today (46.92x)

June 14, 2024

Industry (64.98x)

June 14, 2024

Highest (54.59x)

June 20, 2023


Mutual Fund Holdings

Funds Holdings
SBI Bluechip Fund Direct GrowthSBI Bluechip Fund Direct Growth1.3%
Axis ELSS Tax Saver Fund Direct Plan Growth OptionAxis ELSS Tax Saver Fund Direct Plan Growth Option0.88%
Axis Bluechip Fund Direct Plan GrowthAxis Bluechip Fund Direct Plan Growth0.77%
ICICI Prudential Balanced Advantage Fund Direct Plan GrowthICICI Prudential Balanced Advantage Fund Direct Plan Growth0.44%
SBI Contra Fund Direct GrowthSBI Contra Fund Direct Growth0.74%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Mankind Pharma Ltd shares.

Mankind Pharma Ltd (MANKIND) share price today is ₹2240.6

Mankind Pharma Ltd is listed on NSE

Mankind Pharma Ltd is listed on BSE

  • Today’s highest price of Mankind Pharma Ltd is ₹2275.4.
  • Today’s lowest price of Mankind Pharma Ltd is ₹2227.65.

PE Ratio of Mankind Pharma Ltd is 46.92

PE ratio = Mankind Pharma Ltd Market price per share / Mankind Pharma Ltd Earnings per share

Today’s traded volume of Mankind Pharma Ltd(MANKIND) is 3.74L.

Today’s market capitalisation of Mankind Pharma Ltd(MANKIND) is ₹89750.28Cr.

Mankind Pharma Ltd(MANKINDPrice
52 Week High
52 Week Low

Mankind Pharma Ltd(MANKIND) share price is ₹2240.6. It is down -10.02% from its 52 Week High price of ₹2490

Mankind Pharma Ltd(MANKIND) share price is ₹2240.6. It is up 47.01% from its 52 Week Low price of ₹1524.1

Mankind Pharma Ltd(MANKINDReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns